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Syncope is a common, often perplexing clinical problem
causing emotional stress to patients, their families, and
often, the physicians caring for them. In a large, 26-year
prospective study of men and women ages 30 to 62 years,
3% of men and 3.5% of women experienced at least one
syncopal episode (1). That study excluded adolescent and
elderly populations. Syncope has been reported in up to 47%
of healthy college men (2) and has been shown to have a 6%
one-year incidence in elderly institutionalized patients 75
years and older (3). Although many who experience syncope
do not seek medical advice, syncope accounts for approxi-
mately 3% of emergency room visits and 1% to 6% of
hospital admissions in the U.S. (4,5).
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“Syncope” is defined as a sudden, brief loss of conscious-
ness associated with a loss of postural tone that recovers
spontaneously (6). The differential diagnosis of this symp-
tom is extensive. Syncope may be divided into cardiac,
neurally mediated, and noncardiac causes. Cardiac causes
include organic heart disease such as aortic stenosis, hyper-
trophic cardiomyopathy, dilated cardiomyopathy, pulmo-
nary stenosis, pulmonary hypertension, atrial myxoma,
myocardial infarction, coronary disease, postoperative con-
genital heart disease, cardiac tamponade, and aortic dissec-
tion. Also included in this group are arrhythmias from sinus
node disease, advanced degrees of heart block, pacemaker
malfunction, supraventricular tachycardia, ventricular tachy-
cardia, and torsade de pointes. Neurally mediated causes
include vasovagal syncope, situational syncope, carotid sinus
hypersensitivity, orthostatic hypotension, and postural or-
thostatic tachycardia syndrome. Noncardiac causes encom-
pass neurologic conditions such as migraines, transient
ischemic attacks, seizures, and subclavian steal syndrome.
Other noncardiac causes include metabolic derangements,
hyperventilation, anxiety disorders, major depression, and
hysteria reactions (6–9).
Based on a review of published data between 1984 and
1990, Linzer et al. (8) estimated the cause of syncope to be
neurally mediated in 24%, cardiac in 18%, neurologic in
10%, and psychiatric in 2%. Approximately 34% of cases
remained unexplained. In a more recent review that in-
cluded tilt testing, Alboni et al. (10) found that 58% of
patients had neurocardiogenic syncope, 23% had cardiac
syncope, and 18% of patients remained undiagnosed after
conventional testing.
The prognosis in patients with syncope is variable and
based on the patient’s age, overall health, and cause of
syncope. In healthy persons, neurocardiogenic syncope is
considered a benign entity (1,9). Morbidity, however, may
have a significant impact, especially in the elderly. Mortality
rates in patients with underlying cardiac disease and a
cardiac cause of syncope have been reported at around 30%
(4,11).
The diagnostic dilemma. The diagnosis of syncope is
hampered by its multiple etiologies, sporadic events, diffi-
culty correlating symptoms with clinical data, and lack of a
diagnostic gold standard. The cornerstone evaluation is a
thorough history and physical examination in conjunction
with a baseline electrocardiogram and postural blood pres-
sure measurements. This basic evaluation may be diagnostic
in 26% to 50% of patients (8,10,11). Further testing is
guided by the initial evaluation and may include echocardi-
ography to assess structural or functional pathology, despite
its low diagnostic yield (3%) (10,12).
When arrhythmia is suspected, electrocardiographic
monitoring during a clinical event unambiguously estab-
lishes the diagnosis. Because of sporadic events, Holter
monitoring has only a 5% to 19% diagnostic yield (10,13).
Loop recorders worn for several weeks or months have been
shown to increase diagnostic yield to 35%; however, human
error limits diagnostic efficacy in 32% of patients (14,15).
Patients with known or suspected cardiac disease are at
greatest risk for life-threatening events. Electrophysiologic
(EP) studies in high-risk patients have a 50% diagnostic
yield, including 21% with inducible ventricular tachycardia
and 34% with bradycardia (13). Unfortunately, EP testing
has low sensitivity (37%) in diagnosing transient brady-
arrhythmias and may reveal clinically irrelevant disturbances
in rhythm (16). In patients with structurally normal hearts,
the diagnostic yield of EP testing is low (13).
Patients with suspected neurocardiogenic syncope and
those with unexplained syncope have undergone head-up
tilt testing. Sensitivity of tilt testing with and without
pharmacologic provocation in patients with suspected vaso-
vagal syncope has ranged from 67% to 83%, and positive
tests have been reported in 26% to 90% of patients with
unexplained syncope (13). Using head-up tilt and EP
testing, 26% of patients remain undiagnosed (17). Addi-
tional metabolic or neurologic testing adds little except
expense to the diagnostic yield of syncope unless underlying
medical conditions or focal neurologic signs are present
(4,11).
Implantable loop recorders. In 1995, a novel approach to
the diagnoses of unexplained syncope was reported in 16
patients using an implantable subcutaneous monitoring
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device capable of storing electrograms after patient activa-
tion for up to two years. Using this technique, an etiology
for syncope was established in 94% of patients, with
bradyarrhythmias predominating (18). In a multicenter
series, implantable loop recorders established a symptom-
rhythm correlation in 86% of patients with syncope during
follow-up (19). However, 16% of patients were unable to
properly activate the device, and 4% developed postoperative
wound complications. Of 21 patients with documented
arrhythmias, 18 had bradyarrhythmias and 3 had tachyar-
rhythmias. Potential problems with this technique include
an inability to distinguish bradycardia by mechanism, the
need for an invasive procedure with associated operative
risks, and the possibility of placement in a high-risk patient
who develops a fatal arrhythmia during monitoring (20).
A randomized assessment of the implantable loop re-
corder was recently reported (21). Sixty patients with
unexplained syncope, left ventricular ejection fraction
35%, and history not typical for neurally mediated syn-
cope were randomized into conventional testing (external
loop recorder followed by tilt and EP study) or one-year
prolonged monitoring strategies and given the option of
crossover if the initial evaluation was negative. In this highly
selected study group, prolonged monitoring was more likely
to result in a diagnosis than was conventional testing (55%
vs. 19%). In this issue of the Journal, the cost implications of
this randomized trial were evaluated by Krahn et al. (22).
Using regionalized Canadian cost estimates, this study
concluded that the cost per diagnosis using the prolonged
monitoring strategy was significantly less than the cost of
conventional testing ($5,852 vs. $8,414) despite a higher
initial cost investigation ($2,731 vs. $1,683). A greater
incremental cost effectiveness ratio was reported after com-
bining crossover data. Whether these data can be extrapo-
lated to global investigations of syncope remains unclear;
however, trends derived from this work may promote more
cost-effective diagnostic strategies in selected patients.
Cents and sensibility. The need for cost containment in
the evaluation of syncope has been long recognized. In
1982, the average cost per patient undergoing syncope
evaluation in the U.S. was $2,600, with an estimated cost of
$24,000 per diagnosis (23). Annual per-patient cost has
doubled in recent analysis (24). Estimated costs per diag-
nostic yield for commonly performed tests have been re-
ported to range from $529 for the external loop recorder to
$73,260 for EP testing in patients without structural heart
disease (25). Nontargeted evaluations produce unnecessary
expense, as demonstrated by patients with typical histories
for vasodepressor syncope, in whom baseline testing resulted
in elevated diagnostic costs (up to $16,000) above the cost of
a confirmatory tilt study ($453) (26). In the Canadian study
reported in this issue, 60% of patients underwent nondiag-
nostic neurologic testing before randomization into the
clinical trial at an average cost of $1,327 (22).
Accurate and cost-effective diagnostic strategies must be
employed in the evaluation of syncope. Funding for medical
services is limited, and fiscal waste cannot be tolerated.
Low-yield and unnecessary tests should be avoided. The use
of implantable loop recorders in selected patients helps
further the combination of cost containment and diagnostic
accuracy in unexplained syncope. Targeted, judicious use of
diagnostic testing is imperative in reducing costs and easing
the economic burden of this perplexing and common
medical problem.
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